



LMA International NV

*For Immediate Release*

## **LMA RECEIVES CE MARKING FOR LMA STONEBREAKER™**

**Singapore, 28 June 2006** – Mainboard-listed LMA International N.V. (“LMA”), a global leader in the development and marketing of the LMA™ laryngeal mask airway range of supraglottic airway management devices, has announced that it has received Conformite Europeene (“CE”) marking approval for the revolutionary intra-corporeal lithotripter, LMA StoneBreaker™.

The device has met the requirements of the European Medical Device Directive 93/42/EEC governing the sale and distribution of such medical devices within the European Union and the European Free Trade Area, and with CE marking approval, the LMA StoneBreaker™ can be distributed throughout all 28 countries of the European Economic Area.

The device will be manufactured in Switzerland and distributed via a selection of new and existing LMA distributors. Sales and marketing of the device globally will be managed by LMA Urology Suisse Ltd, a company incorporated in Switzerland, and its own sales team. A 510(k) application is expected to be filed with the FDA for the US market in the second half of 2006.

Mr John Lim, Group President of LMA, said, “We are pleased to have obtained CE mark approval. Following the clinical trials completed in 2005, there has been overwhelming demand for the product from clinicians and urologists around the world and we are eager to commence sales of the StoneBreaker™ in Europe in the early second half of this year.

We anticipate exciting growth potential for this product globally. More than 2 million people in the US and Europe are affected by kidney stones every year and the incidence of this disease is increasing worldwide, including in emerging markets such as China, India and South America, where access to adequate and cost-effective treatments are limited.”

The innovative and portable device effectively fragments and removes stones in the entire urinary tract. Weighing around 500 grams with a probe, the LMA StoneBreaker™ does not require any extraneous electrical or pneumatic connections. It is powered by a detachable cartridge of high pressure carbon dioxide gas, with a maximum pre-adjusted operating pressure of 31 bars.

Sales from the LMA StoneBreaker™ are expected to contribute positively to LMA’s performance for the financial year ending 31 December 2007.

- Ends -

**For media queries, please contact**

Sharon Seetho, Gavin Anderson & Company Singapore, +65 6339 9110

**LMA International NV**

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA-Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Germany and San Diego, California. DBS Bank Limited and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.